- Home
- BMEA
BMEA
Biomea Fusion Inc.
as 11-21-2024 4:00pm EST
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 275.6M | IPO Year: | 2021 |
| Target Price: | $37.25 | AVG Volume (30 days): | 814.9K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $22.74 | Next Earning Date: | 10-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Biomea Fusion Inc. (BMEA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | BMEA | Director | Sep 30 '24 | Buy | $10.06 | 10,000 | $100,600.00 | 15,000 |
Latest Biomea Fusion Inc. News
BMEA Breaking Stock News: Dive into BMEA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
Simply Wall St.
8 days ago
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
GlobeNewswire
20 days ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
22 days ago
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
GlobeNewswire
23 days ago
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
GlobeNewswire
a month ago
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
GlobeNewswire
a month ago
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
TipRanks
a month ago
Morning Movers: Arcadium Lithium surges after deal to be acquired
Compare BMEA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMEA Biomea Fusion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.